HER2 Alterations in Non-Small Cell Lung Cancer

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.